Ribocicib

Brand name: Kisgalli

DILI Likelihood

Score C — Probable Hepatotoxin

This drug is probably linked to idiosyncratic liver injury, but has been reported uncommonly and no characteristic signature has been identified.

Fewer than 12 cases without a significant case series.

Classification

Primary class Antineoplastic

Secondary class Breast Cancer

FDA approval 2017

No article link available. Search directly at livertox.nih.gov.